AIFORIA Stock Overview
Together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software for translating images into discoveries, decisions, and diagnoses in Finland, rest of Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aiforia Technologies Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.00 |
| 52 Week High | €4.90 |
| 52 Week Low | €3.17 |
| Beta | 0.37 |
| 11 Month Change | -1.23% |
| 3 Month Change | -11.50% |
| 1 Year Change | 19.76% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| AIFORIA | FI Healthcare Services | FI Market | |
|---|---|---|---|
| 7D | -8.0% | 3.9% | -1.5% |
| 1Y | 19.8% | -10.2% | 1.5% |
Return vs Industry: AIFORIA exceeded the Finnish Healthcare Services industry which returned -11.1% over the past year.
Return vs Market: AIFORIA exceeded the Finnish Market which returned 3.5% over the past year.
Price Volatility
| AIFORIA volatility | |
|---|---|
| AIFORIA Average Weekly Movement | 4.8% |
| Healthcare Services Industry Average Movement | 5.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in FI Market | 6.6% |
| 10% least volatile stocks in FI Market | 2.6% |
Stable Share Price: AIFORIA has not had significant price volatility in the past 3 months compared to the Finnish market.
Volatility Over Time: AIFORIA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 78 | Jukka Tapaninen | www.aiforia.com |
Aiforia Technologies Oyj, together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software for translating images into discoveries, decisions, and diagnoses in Finland, rest of Europe, North America, and internationally. The company offers AI-supported image-based diagnostic suites for breast cancer, lung cancer, and prostate cancer. It also provides Aiforia Create, which allows users to create and validate their own proprietary deep learning AI models, as well as train their AI models to identify, quantify, or measure features in any 2D image; and Aiforia Studies, a software module that offers AI-assisted image analysis workflow within the framework of good laboratory practices.
Aiforia Technologies Oyj Fundamentals Summary
| AIFORIA fundamental statistics | |
|---|---|
| Market cap | €115.38m |
| Earnings (TTM) | -€12.36m |
| Revenue (TTM) | €2.81m |
41.1x
P/S Ratio-9.3x
P/E RatioIs AIFORIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIFORIA income statement (TTM) | |
|---|---|
| Revenue | €2.81m |
| Cost of Revenue | €7.56m |
| Gross Profit | -€4.75m |
| Other Expenses | €7.61m |
| Earnings | -€12.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 14, 2025
| Earnings per share (EPS) | -0.43 |
| Gross Margin | -168.96% |
| Net Profit Margin | -439.98% |
| Debt/Equity Ratio | 27.7% |
How did AIFORIA perform over the long term?
See historical performance and comparison